BPI-221351 | m-entrepreneurship.com

Product Name :
BPI-221351

Search keywords :
IDH2

drugId :
null

Target Vo:
Isocitrate dehydrogenase [NADP] cytoplasmic

Target Vo Short Name :
IDH1

Moa_Name:
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Betta Pharmaceuticals Co Ltd

Active Company_Name :
Betta Pharmaceuticals Co Ltd

Active Indication_Name:
Solid tumours

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Etigilimab supplier
Stathmin Rabbit mAb Purity & Documentation
PAX6 Antibody: PAX6 Antibody is an antibody targeting to PAX6.

Author: Betaine hydrochloride

Related Posts